转自：北京日报客户端 对于新增的114种药品，陈昊强调，对患者而言，医保目录动态调整且总体呈增多趋势，临床医生和患 者的用药选择性都得到增强，能更好满足患者需求，尤其是创新药纳入速度和数量增加，这是非常积极 的现象。虽然创新药纳入会给医保基金带来一定支付压力，但医保部门有总额预算控制、DRG/DIP单病 种付费打包机制以及合理用药管理等多种管理工具，只要临床坚持合理用药，短时内不会对医保基金造 成太大压力，医保基金承受是没有太大问题的。 "未来，患者需要听从医务人员等专业人员的指导，由临床专业人士判断原有用药是否需要延续，并制 定和调整用药方案，切勿自行用药。医保目录内药品均为处方药，具体用药种类和方式需由医务人员决 定，患者应信任医务人员和医学技术，无需过度担忧。"陈昊说。 来源：人民日报健康客户端 作者: 高瑞瑞 一位居民 正在当地医院窗口处取药。高瑞瑞摄 记者了解到，被调出的29种药中，有21种西药和8种中成药，多款药品都在医保目录中有替代选项。华 中科技大学同济医学院药品政策与管理研究中心主任、高级经济师陈昊告诉人民日报健康客户端记 者，"医保目录实行动态调整，这是正常现象。"华中科技大学同济医学院药 ...

Core Viewpoint - Shanghai Kaibao (300039.SZ) announced that it and its wholly-owned subsidiary, Shanghai Kaibao Xinyi (Xinxiang) Pharmaceutical Co., Ltd., have a total of 92 drugs included in the National Medical Insurance Directory, with 50 classified as Category A and 42 as Category B [1] Group 1: Drug Inclusion in National Medical Insurance Directory - The company has three exclusive products (Tanreqing Injection, Tanreqing Capsules, and Qishen Capsules) and one exclusive dosage form (Duo Suo Tea Alkaloid Capsules) continuing in the National Medical Insurance Directory (2025) [1] - The company's products Linggui Zhugan Decoction Granules, Yiguan Decoction Granules, and the subsidiary's Duo Suo Tea Alkaloid Tablets are included in the National Medical Insurance Directory (2025) [1] - The exclusive product Tanreqing Capsules remains in the National Medical Insurance Directory (2025) with a reimbursement standard of 4.09 yuan per (0.4g/piece), valid from January 1, 2026, to December 31, 2027 [1] Group 2: Changes in Drug Status - The subsidiary's products, Compound Robama Tablets and Baldness Pills, have been removed from the National Medical Insurance Directory (2025) [1] - Currently, the removal of the aforementioned products from the insurance directory has no substantial impact on the company's operating performance [1] - Other products' inclusion in the National Medical Insurance Directory (2025) remains unchanged compared to the National Medical Insurance Directory (2024) [1]

Core Viewpoint - Shanghai Kaibao (300039.SZ) announced that it and its wholly-owned subsidiary, Shanghai Kaibao Xinyi (Xinxiang) Pharmaceutical Co., Ltd., have a total of 92 drugs included in the National Medical Insurance Directory, with 50 classified as Category A and 42 as Category B [1] Group 1 - The company has three exclusive products (Tan Re Qing injection, Tan Re Qing capsules, and Qi Shen capsules from the subsidiary) and one exclusive dosage form (Duo Suo Tea Alkaloid capsules) that continue to be included in the National Medical Insurance Directory (2025) [1] - The company's products Ling Gui Zhu Gan Tang granules, Yi Guan Jian granules, and the subsidiary's Duo Suo Tea Alkaloid tablets are also listed in the National Medical Insurance Directory (2025) [1] - The exclusive product Tan Re Qing capsules remains in the National Medical Insurance Directory (2025) with a reimbursement standard of 4.09 yuan per (0.4g/piece), with the agreement valid from January 1, 2026, to December 31, 2027 [1] Group 2 - The subsidiary's products, Compound Luo Bu Ma tablets and Ban Hu Wan, have been removed from the National Medical Insurance Directory (2025), but this adjustment has no substantial impact on the company's operating performance [1] - Other products' inclusion in the National Medical Insurance Directory (2025) remains unchanged compared to the National Medical Insurance Directory (2024) [1]